![](/images/graphics-bg.png)
Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
المؤلفون المشاركون
Palla, Ilaria
Kheiraoui, Flavia
de Waure, Chiara
Iaccarino, Luca
La Torre, Giuseppe
Nicolotti, Nicola
Gliubizzi, Daniela
Ricciardi, Gualtiero
Capizzi, Silvio
Pierotti, Francesca
Veneziano, Maria Assunta
Gualano, Maria Rosaria
Sferrazza, Antonella
Turchetti, Giuseppe
Di Nardo, Francesco
Cadeddu, Chiara
Porcasi, Rolando
Doria, Andrea
Pippo, Lara
Di Pietro, Maria Luisa
Specchia, Maria Lucia
المصدر
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-08-17
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Objective.
Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics.
Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease.
This paper summarizes a health technology assessment performed in Italy.
Methods.
SLE epidemiology and burden were assessed using the best published international and national evidences and efficacy and safety of belimumab were synthesized using clinical data.
A cost-effectiveness analysis was performed by a lifetime microsimulation model comparing belimumab to standard of care (SoC).
Organizational and ethical implications were discussed.
Results.
Literature review showed that SLE affects 47 per 100,000 people for a total of 28,500 patients in Italy, 50% of whom are affected by active form of the disease despite SoC.
These patients, if autoantibodies and anti-dsDNA positive with low complement, are eligible for belimumab.
SLE determines work disability and a 2–5-fold increase in mortality.
Belimumab with SoC may prevent 4,742 flares in three years being cost-effective with an incremental cost-effectiveness ratio of €32,859 per quality adjusted life year gained.
From the organizational perspective, the development of clear and comprehensive clinical pathways is crucial.
Conclusions.
The assessment supports the use of belimumab into the SLE treatment paradigm in Italy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Specchia, Maria Lucia& de Waure, Chiara& Gualano, Maria Rosaria& Doria, Andrea& Turchetti, Giuseppe& Pippo, Lara…[et al.]. 2014. Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International،Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-491904
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Specchia, Maria Lucia…[et al.]. Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International No. 2014 (2014), pp.1-9.
https://search.emarefa.net/detail/BIM-491904
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Specchia, Maria Lucia& de Waure, Chiara& Gualano, Maria Rosaria& Doria, Andrea& Turchetti, Giuseppe& Pippo, Lara…[et al.]. Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-491904
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-491904
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)